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Activated phosphoinositide 3-kinase δ syndrome (APDS)1 is caused by gain-of-function mutations in PIK3CD, which encodes 
the catalytic p110δ subunit of phosphoinositide 3 kinase. We describe three patients with APDS1, the first thereof in Korea. There-
in, we investigated clinical manifestations of APDS1 and collected data on the efficacy and safety profile of sirolimus, a mammalian 
target of rapamycin inhibitor and pathway-specific targeted medicine. The same heterozygous PIK3CD mutation was detected in 
all three patients (E1021K). After genetic diagnosis, all patients received sirolimus and experienced an excellent response, includ-
ing amelioration of lymphoproliferation and improvement of nodular mucosal lymphoid hyperplasia in the gastrointestinal tract. 
The median trough level of sirolimus was 5.5 ng/mL (range, 2.8–7.5) at a dose of 2.6–3.6 mg/m2. Two patients who needed high-
dose, short-interval, immunoglobulin-replacement treatment (IGRT) had a reduced requirement for IGRT after initiating siroli-
mus, and the dosing interval was extended from 2 and 3 weeks to 4 weeks. The IgG trough level after sirolimus treatment (median, 
594 mg/dL; range, 332–799 mg/dL) was significantly higher than that before sirolimus treatment (median, 290 mg/dL; range, 
163–346 mg/dL) (p<0.001). One episode of elevated serum creatinine with a surge of sirolimus (Patient 2) and episodes of neutro-
penia and oral stomatitis (Patient 1) were observed. We diagnosed the first three patients with APDS1 in Korea. Low-dose siroli-
mus may alleviate clinical manifestations thereof, including hypogammaglobulinemia. 
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Activated phosphoinositide 3-kinase δ syndrome (APDS) is a 
primary immunodeficiency (PID) caused by hyperactivity of 
phosphatidylinositol-3-OH kinase.1,2 APDS1 is caused by gain-
of-function mutations in PIK3CD, and APDS2 is caused by loss-
of-function mutations in PIK3R1.3,4 Both gene mutations result 
in hyperactivity of the PI3K/Akt/mammalian target of rapamy-
cin (mTOR) signaling pathway, leading to lymphoproliferation 
and immunosuppression.5,6 Here, we describe three patients 
with a heterozygous PIK3CD mutation treated with sirolimus, 
an mTOR inhibitor, which alleviated the hypogammaglobu-
linemia, lymphoproliferation, and enteropathy. This study was 
approved by the Institutional Review Board of Samsung Medi-
cal Center (IRB File No.2018-0013).
A 4-year-old male (Patient 1) diagnosed with common vari-
able immunodeficiency (CVID) was referred to our clinic for 
persistent lymph node enlargement, hematochezia, and in-
creased serum immunoglobulin (Ig)M. His medical history in-
cluded double barrel enterostomy and segmental resection of 
the small intestine, attributable to intestinal malrotation and 
perforation in the neonatal period. He was diagnosed with he-
molytic anemia at the age of 10 months and pancytopenia at 
the age of 15 months, after which he received steroid treatment. 
At the age of 21 months, he exhibited increased IgM (304 mg/dL; 
normal, 43–173 mg/dL) and decreased IgG (16 mg/dL; normal, 
345–1236 mg/dL) and IgA (<1 mg/dL; normal, 11–106 mg/dL). 
Regular immunoglobulin-replacement treatment (IGRT, 500 
mg/kg every 3 weeks) was initiated for CVID. At the age of 10 
months, a lymph node biopsy revealed atypical lymphoid cell 
proliferation. At the age of 3 years, hematochezia gradually in-
creased, and IgG trough levels were not well maintained (av-
erage, 333 mg/dL; normal, 345–1236 mg/dL) despite IGRT (500 
mg/kg every 3 weeks). Patient 1 had a head circumference of 
55 cm (>95th percentile) and body weight of 15 kg (<10th per-
centile), as well as multiple enlarged cervical lymph nodes and 
splenomegaly. Complete blood count values were white blood 
cells (WBC), 7910/μL (normal, 6000–15000/μL); hemoglobin 
(Hb), 10.9 g/dL (normal, 10.5–14.0 g/dL); and platelets (PLT), 
122 k/μL (normal, 150–450 k/μL). Immunological values were 
CD3, 68%, 2320/μL (normal: 56–75%, 1400–3700/μL); CD4, 19%, 
648/μL (normal: 28–47%, 700–2200/μL); CD8, 45%, 1535/μL 
(normal: 16–30%, 490–1300/μL); and CD19, 10%, 341/μL (nor-
mal: 8–39%, 180–1300/μL). Serum IgG, A, and M levels were 
332 mg/dL (normal, 345–1236 mg/dL), <1 mg/dL (normal, 14–
159 mg/dL), and 569 mg/dL (normal, 43–207 mg/dL), respec-
tively (Table 1). Mucosal nodular lymphoid hyperplasia visu-
alized as cobblestone-like polyps and cytomegalovirus (CMV) 
was detected in a mucosal biopsy through colonoscopy. Diag-
nostic exome sequencing results revealed a heterozygous 
E1021K mutation in PIK3CD, which was confirmed via Sanger 
sequencing. After treatment with oral valganciclovir (VGCV) 
for 6 weeks, follow-up colonoscopy results showed eradication 
of CMV in the colon, but mucosal nodular lymphoid hyperpla-
sia and hematochezia persisted. Subsequently, sirolimus was 
started, and trough sirolimus levels were maintained around 
5 ng/mL at a dose of 2 mg (3.0 mg/m2). Upon treatment, diar-
rheal episodes decreased, weight increased, and lymph node 
enlargement disappeared. After 6 months of treatment, a fol-
low-up colonoscopy showed improved mucosal nodular lym-
phoid hyperplasia and decreased cobblestone lesions on the 
duodenal bulb. Currently, he is receiving regular follow-up vis-
its and has no signs of major invasive infection or any compli-
cations. However, the low IgG level has not fully recovered. 
Therefore, IGRT is regularly administered with prolonged in-
tervals (extended from 800 mg/kg every 2 weeks to 800 mg/kg 
every 4 weeks) (Fig. 1G). Neutropenia and oral stomatitis im-
proved during sirolimus treatment after administering inter-
mittent granulocyte colony-stimulating factor. No other seri-
ous adverse events were noted. 
A 4-year-old male (Patient 2) with a history of idiopathic throm-
bocytopenic purpura, Bacillus Calmette-Guérin vaccine site in-
fection, and respiratory tract infection requiring hospitalization 
was referred to our clinic for enlargement of multiple lymph 
nodes suspicious for lymphoma. Cervical lymph node enlarge-
ment was first noticed at 31 months old. At the age of 3 years, 
decreased IgG (89 mg/dL) with elevated IgM (347 mg/dL) and 
normal IgA (16 mg/dL) were detected at a prior hospital. He 
received regular IGRT under the interim diagnosis of CVID; 
however, trough IgG levels remained below 400 mg/dL despite 
receiving a higher IGRT dose (800 mg/kg) every 3 weeks. Patient 
2 had a head circumference of 52.8 cm (95th percentile) and 
body weight of 17 kg (25–50th percentile). Multiple enlarged 
lymph nodes in the cervical, supraclavicular, and inguinal ar-
eas were palpated, and massive splenomegaly was noted. Mol-
loscum contagiosum was observed on his buttocks. Complete 
blood count results included WBC, 3300/μL; Hb, 13.1 g/dL; 
and PLT, 157k/μL. Immunological values were CD3, 867/μL 
(normal, 1578–3707/μL); CD4, 241/μL (normal, 870–2144/μL); 
CD8, 613/μL (normal, 472–1107/μL); and CD19, 24/μL (nor-
mal, 276–640/μL). The CD4:CD8 ratio was 0.39 (Table 1). Posi-
tron emission tomography/computed tomography (PET/CT) 
findings showed enlargement of multiple lymph nodes, includ-
ing the bilateral cervical, supraclavicular, and inguinal areas, 
and abnormal uptake in the whole intestine. A colonoscopy 
revealed multiple nodules and masses throughout the entire 
length of the colon. Cervical lymph node and large intestine 
biopsies revealed atypical lymphocyte proliferation with poly-
clonality (Fig. 1A–C) (Supplementary Fig. 1A and B, only on-
line). The PIK3CD mutation (E1021K, heterozygous) was de-
tected using diagnostic exome sequencing and confirmed via 
Sanger sequencing. Sirolimus treatment was initiated after 
APDS1 diagnosis at 2 mg per day (2.9 mg/m2), increasing to 2.5 
mg (3.6 mg/m2) after 2 weeks. Corresponding sirolimus trough 
levels were 4.4–6.9 ng/mL. The cervical lymph nodes almost 
disappeared after 1 month; however, high-dose IGRT was still 
required. We increased the sirolimus dosage to 3 mg per day 
(4.3 mg/m2); however, after 20 days, sirolimus trough levels 
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abruptly rose to 14.7 ng/mL, and serum creatinine levels rose 
from baseline 0.28 to 0.45 mg/dL. After 3 days of withdrawal, 
the trough level decreased to 9.6 ng/mL, with normalization 
of creatinine levels. Sirolimus was restarted at a dose of 2.5 mg 
and maintained. Currently, the patient’s IgG trough levels re-
main above 400 mg/dL with IGRT (500–600 mg/kg every 4 
weeks). Significant improvement of multiple lymphoid hyper-
plasia was noted after 6 months (Fig. 1D–H). However, a colon 
biopsy revealed CMV, and the patient complained of diarrhea 
(Supplementary Fig. 1C, only online). Consequently, VGCV was 
administered for 6 weeks. Presently, there is no evidence of bone 
marrow suppression or mucositis and no infectious complica-
tions requiring hospitalization.
A 13-year-old female (Patient 3) previously diagnosed with 
selective IgA deficiency was reevaluated for other PIDs when 
she presented with multiple episodes of prolonged fever and 
enlargement of several lymph nodes. Patient 3 had a history 
of hospitalizations attributable to recurrent respiratory tract 
infections, cellulitis, and osteomyelitis. She was diagnosed with 
selective IgA deficiency at the age of 4 years at our hospital. 
Cervical lymph node enlargement was first noticed at the age 
of 6 years; hematochezia was also noted. Colon and cervical 
lymph node biopsies showed atypical lymphocyte prolifera-
tion with polyclonality, and persistent atypical lymphoid pro-
liferation of the colon was observed at the age of 10 years. One 
colon biopsy specimen was suspicious for mucosa-associated 
lymphoid tissue lymphoma. The oncologists decided to ob-
serve the patient without special chemotherapy. During the 
follow-up period, we diagnosed and treated Patient 1 from the 
present case series, leading the clinicians to reevaluate Patient 
3 for other PIDs. Upon reevaluation, the height and weight of 
Patient 3 were below the 5th percentile and development was 
Table 1. Clinical and Immunological Manifestations of APDS1 in Three Patients
Age at genetic diagnosis/sex
Patient 1 Patient 2 Patient 3
4 yr, male 4 yr, male 13 yr, female
Family history of PID N N N
Infectious complications
BCGiosis N √ (3 month) √ (unknown)
Recurrent respiratory infections √ (infant) √ (infant) √ (infant)
CMV colitis √ (4 yr) √ (4 yr) N
Tonsillitis (with tonsillectomy) √ (43 month) N N
Osteomyelitis N N √ (4 yr)
Non-infectious complications
Lymphadenopathy √ (27 month) √ (38 month) √ (4 yr)
Splenomegaly √ (4 yr) √ (43 month) √ (10 yr)
Hepatomegaly N N √ (10 yr)
Cytopenia √ (10 month) √ (2 month) N
Nodular mucosal lymphoid hyperplasia of the intestine √ (4 yr) √ (43 month) √ (6 yr)
Hematochezia/diarrhea √ (17 month) √ (50 month) √ (6 yr)
Poor weight gain 5–10 p 25–50 p 3 p
Macrocrania (> 95 p) √ √ N
Lymphoma N N N
Bronchiectasis N N √





















PHA stimulation* Decreased (4 yr) sl. Decreased (4 yr)
nl (4 yr)
absent (12 yr)
CD16 CD56 cell count nl (4 yr) nl (4 yr) nl (12 yr)
Immunoglobulins IgG ↓↓, IgA ↓, IgM ↑ (4 yr) IgG ↓↓, IgA ↓, IgM ↑ (4 yr) IgG ↑↑, IgA ↓, IgM ↑ (12 yr)
The numbers in parentheses indicate the age of symptom onset or the age at the laboratory test.
√, present; ↑, increased abundance; ↓, decreased abundance; nl, normal; N, none; APDS, activated phosphoinositide 3-kinase δ syndrome; PID, primary immuno-
deficiency disease; BCGiosis, Bacillus Calmette-Guérin vaccine site infection; CMV, cytomegalovirus; PHA, phytohemagglutinin; p, percentile.
*Because of laboratory limitations, QuantiFERON-TB Gold Tests were used. 
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normal. At the age of 12 years, laboratory values were WBC, 
5410/μL; Hb, 8.5 g/dL; and PLT, 285k/μL. Immunological val-
ues were CD3, 391/μL (normal, 800–3500/μL); CD4, 194/μL 
(normal, 400–2100/μL); CD8, 190/μL (normal, 200–1200/μL); 
and CD19, 54/μL (normal, 200–600/μL). The CD4:CD8 ratio 
was 1.02. The response to phytohemagglutinin mitogen was 
reduced, while results from the same test performed 8 years 
prior were normal. Serum IgG, A, and M levels were 1920 mg/
dL (normal, 639–1349 mg/dL), 3 mg/dL (normal, 70–312 mg/
dL), and 1138 mg/dL (normal, 56–352 mg/dL), respectively. 
Hypermetabolic enlarged lymph nodes, splenomegaly, and 
bronchiectatic changes in the middle lobe of the right lung 
were observed on PET/CT. Diagnostic exome sequencing re-
vealed a heterozygous E1021K mutation in PIK3CD, which was 
confirmed via Sanger sequencing. Sirolimus was initiated at 3 
mg per day (2.55 mg/m2), with trough levels of 4.6–6.7 ng/mL. 
There were no adverse events, the hematochezia improved, 
and the size of the lymph nodes decreased. Patient 3 was in 
the 50–75th percentile for body weight and height at the age of 
5 years, but had poor growth from 5 to 13 years of age. However, 
she rapidly gained weight with sirolimus treatment (2 kg be-
tween 12–13 years before treatment compared to 6 kg between 
13–14 years after treatment), and height percentile changes 
were observed (<3rd percentile before to 5–10th percentile af-
ter treatment) (Supplementary Fig. 2, only online). 
This is the first case series of sirolimus treatment in Korean 
patients with APDS1. We have described the detailed clinical 
responses to sirolimus treatment, which will help other clini-
cians who try this therapeutic option. Some adverse events (el-
evation of serum creatinine at higher doses, neutropenia, and 
stomatitis) were observed, although they were manageable. 
Patients with APDS can exhibit numerous clinical manifes-
tations at various ages.1,2 In 53 APDS patients from a large co-
hort study,2 recurrent respiratory tract infection was the most 
frequently observed complication (95%), followed by lymphade-
nopathy (64%), bronchiectasis (60%), and splenomegaly (58%). 
Enteropathy (25%) and nodular mucosal lymphoid hyperpla-
sia (32%) were observed in a relatively small portion of patients. 
All 3 patients in our series had intestinal nodular mucosal lym-
phoid hyperplasia. Patient 2 showed abnormal uptake on PET/
CT in the intestine, and massive nodular mucosal lymphoid 
hyperplasia was detected, although he had no gastrointestinal 
symptoms. Therefore, physicians may consider an initial gas-
trointestinal endoscopic evaluation in APDS1 patients regard-
less of symptoms.
Activation of PI3K/Akt/mTOR signaling leads to lymphoid 
proliferation via the nuclear factor kappa B pathway; therefore, 
inhibiting PI3K overexpression or its downstream pathway may 
help alleviate the disease course.5-7 Sirolimus, everolimus, and 
temsirolimus, as well as leniolisib have been introduced as path-
way-based targeted therapies in patients with APDS.2,8,9 Recently, 
a study of 77 APDS patients reported that lymphoproliferation 
responded well to sirolimus in 26 patients, with less response 
to gut inflammation and cytopenia: there was no mention of 
hypogammaglobulinemia or changes in IGRT requirement 
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Fig. 1. Comparison of the clinical features and histologic findings before and after treatment with sirolimus (Patient 2) and trough immunoglobulin (Ig)G 
levels before and after sirolimus treatment (Patient 1 and Patient 2). (A–F) Positron emission tomography/computed tomography (PET/CT), colonoscopy, 
and colon biopsy findings before and after 6 months of treatment with sirolimus in Patient 1. PET/CT revealed enlargement of multiple lymph nodes, in-
cluding bilateral cervical lymph nodes (A), and colonoscopy revealed multiple nodules and masses throughout the entire length of the colon (B). Biopsy of 
the colon specimen showed lymphoid cell aggregates and surface erosion (C). After 6 months of treatment with sirolimus, the uptake observed in the 
lymph nodes and spleen on PET/CT almost disappeared (D), and lymphoid aggregations in the colon were significantly improved (E) and (F). Changes in 
IgG and sirolimus trough levels following treatment with sirolimus are shown (G). The IgG trough level after sirolimus treatment (median, 594 mg/dL; range, 
332–799 mg/dL) was significantly higher than before sirolimus treatment (median, 290 mg/dL; range, 163–346 mg/dL) (p<0.001) (H).
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rolimus, and their symptoms responded well to treatment. The 
immunoglobulin dose was reduced in two patients requiring 
high-dose, short interval regular IGRT. Trough IgG levels were 
significantly higher after sirolimus treatment than before (Fig. 
1G and H). Improvements in enteropathy leading to protein-
losing gastroenteropathy possibly explains the reduced sever-
ity of hypogammaglobulinemia. Diarrheal symptoms signifi-
cantly improved upon sirolimus treatment, while low IgA and 
high IgM levels were unchanged. Although IGRT doses and in-
tervals were improved (Patients 1 and 2), IGRT could not be dis-
continued.
Safety and efficacy data for sirolimus in APDS patients are 
limited. The median trough level of sirolimus in our patients 
was on the lower side of the range used to prevent graft rejection 
in kidney or heart transplant recipients (4–12 ng/mL).11 Two 
patients in this series experienced adverse events. Patient 1 suf-
fered from granulocytopenia and oral stomatitis, and Patient 
2 experienced elevations in serum creatinine with an abrupt 
surge in sirolimus trough levels when increasing the dose. Com-
plications from treatment with sirolimus have also been report-
ed elsewhere,10 in which four patients completely stopped the 
medication due to poor compliance (2 patients) and headache, 
vomiting, and nephrotoxicity (2 patients). Further, three patients 
temporarily stopped sirolimus attributable to aphthous ulcer, 
hepatotoxicity, and renal toxicity. A lower target range of siro-
limus has been suggested for APDS patients than for solid or-
gan transplant recipients.8 We propose the use of sirolimus with 
a lower range of trough levels alongside precise monitoring of 
blood cell counts and renal function to avoid renal toxicity and 
other complications, including possible opportunistic infec-
tions related to neutropenia. The efficacy and safety of long-
term sirolimus use in patients with APDS remain uncertain, 
and the role of sirolimus in APDS patients with complications 
of malignant tumors, such as lymphoma, is also unclear. Siroli-
mus treatment in APDS patients should be followed long term.
In conclusion, we report three patients with APDS1 for the 
first time in Korea. A low-dose mTOR inhibitor might relieve 
severe hypogammaglobulinemia, as well as lymphoprolifera-
tion and enteropathy, without major adverse effects in patients 
with APDS1. 
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